Quote | Appili Therapeutics Inc. (TSXC:APLI:CC)
Last: | $0.07 |
---|---|
Change Percent: | 0.0% |
Open: | $0.07 |
Close: | $0.07 |
High: | $0.07 |
Low: | $0.0675 |
Volume: | 87,908 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Appili Therapeutics Inc. (TSXC:APLI:CC)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 ...
Message Board Posts | Appili Therapeutics Inc. (TSXC:APLI:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc. Company Name:
APLI:CC Stock Symbol:
TSXC Market:
Appili Therapeutics Inc. Website:
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL launched and commercial sales ongoing Funding commitments from U.S. Air Force Academy intended to advance ATI-1701 toward an IND submission to the FDA Engaging regulatory authorities to align on ATI-1801 ...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmac...